Australia's most trusted
source of pharma news
Posted 4 February 2026 AM
Australia is spearheading the world-first clinical trial of Providence Therapeutics’ personalised cancer vaccine for children and adolescents with some of the most aggressive and treatment-resistant brain cancers.
The Canadian mRNA medicines platform company has partnered with the University of Queensland and the South Australian Health and Medical Research Institute (SAHMRI), which will co-lead the project after receiving $2.578 million in funding from the Australian Government.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.